NeuroLeap

NeuroLeap operates at the intersection of applied neuroscience, health care, and brain-computer-interface technology. Its described approach combines non-invasive brain mapping and neurometric assessment with neurofeedback-oriented programs, spanning assessment and cognitive or mental-wellness support. That combination distinguishes its stated offering from a profile centered only on general wellness: NeuroLeap describes measuring brain activity and using the resulting information to inform personalized improvement programs. The company also lists a pre-university program, extending its stated audience to students as well as people seeking broader cognitive or mental-health support. The available company profile does not identify verifiable named competitors or provide enough comparable product, revenue, or clinical-outcome data to rank NeuroLeap against specific neuroscience businesses. Its market position is therefore best described by its product focus, rather than by unsupported claims of leadership or market share. Its distinguishing elements are the BCI-based assessment, QEEG brain mapping, and the pairing of measurement with neurofeedback and proprietary protocols. The company describes its work as evidence-based and references FDA registration for relevant parts of its approach.

NeuroLeap’s documented trajectory begins with its 2017 founding and an angel financing round announced on October 9, 2019. A later identifiable milestone is the November 18, 2021 MoU with IIT Mandi for brain-computer interfaces, indicating an academic collaboration around a core technology area. The company’s described product range encompasses a brain-function assessment, a personalized enhancement program, and a pre-university program. No later financing round, launch date, or quantified commercial milestone is provided. Overall, the available evidence shows an early funding event, a subsequent research-related collaboration, and a broadening set of described programs, but does not establish the pace or scale of growth since 2021.